How we used VR and AR to create connections between physicians and patients.
Bhavesh Ashar was tapped as senior VP and head of Oncology for Bayer’s Pharmaceuticals Division in the United States. Ashar reports to Carsten Brunn, head of Bayer Pharmaceuticals for the Americas region.
John DeMay has been appointed president, Astellas US Technologies Inc. (AUST).
Robert H. Ring, Ph.D., was appointed CEO and Jeffrey Stevenson was made chairman of the board of directors for Vencerx Therapeutics.
Mark Fladrich has taken over the position of chief commercial officer at the Grünenthal Group and now is responsible for the entire global commercial organization.
Michael McMyne joined Valeant Pharmaceuticals International Inc.’s dermatology division as VP of sales, and Stacey Williams joined as VP of marketing. Additionally, the company announced Lainie Keller joined as VP of corporate communications.
Daniel Menichella is appointed CEO of CureVac Inc., the Boston-based U.S. subsidiary of CureVac AG.
Paul M. Bisaro was made president and CEO as well as a member of the board of directors of Impax Laboratories Inc.
Walter H. Moos, Ph.D., was appointed CEO of ShangPharma Innovation.